Skip to Content
Stock Analyst Update

Boosting Fair Value on Alnylam After Drug Trial

Based on the stellar results and clean safety profile, we think patisiran will likely receive approval in the U.S. and Europe in 2018, which drives our fair value change and peak sales estimates near $1 billion.

Mentioned:

We are raising  Alnylam's (ALNY) fair value estimate to $92 per share from $74 to reflect positive phase 3 results evaluating the company’s lead drug patisiran in a type of hereditary amyloidosis neuropathy. Based on the stellar results and clean safety profile, we think the drug will likely receive approval in the U.S. and Europe in 2018, which drives our fair value change and peak sales estimates near $1 billion. Given our already limited expectations for Ionis’ competing amyloidosis drug inotersen due to safety concerns, we do not plan on adjusting our $46 per share fair value estimate for the company. Last month, Ionis’ partner GlaxoSmithKline opted out of inotersen commercialization. Ionis’ resulting increased profit share is offset by our lower expectations for the drug in our model, despite a more convenient administration than Alnylam’s patisiran.

Patisiran’s gene-silencing mechanism showed impressive efficacy across a broad spectrum of patients with hereditary ATTR amyloidosis with polyneuropathy, including those with cardiac involvement, which could set the drug up for a broader label than expected. Hereditary ATTR amyloidosis is a rare disease with high unmet need that has been historically categorized as familial amyloid cardiomyopathy (or FAC, accumulation of amyloid in the heart) and familial amyloid polyneuropathy (or FAP, accumulation of amyloid in the nerves), but today the industry views the disease as more of a spectrum (FAP typically precedes FAC). Alnylam’s phase III Apollo trial met its primary and secondary endpoints and showed no serious side effect imbalances against the placebo arm. Despite patisiran’s less convenient intravenous dosing, which requires the use of steroid pre-treatment, we believe the drug’s clean safety profile makes it an easy winner against Ionis’ inotersen. Alnylam’s next-generation drug ALN-TTRsc02, with subcutaneous dosing every couple of months, decreases the chance that Ionis’ drug will take meaningful market share.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Kelsey Tsai does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.